We are live on ! Find out more
CRGX

CARGO Therapeutics

Delisted

CRGX was delisted on the 18th of August, 2025.

73 hedge funds and large institutions have $716M invested in CARGO Therapeutics in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

94% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 16

12% more funds holding

Funds holding: 6573 (+8)

2.68% more ownership

Funds ownership: 92.45%95.13% (+2.7%)

12% less capital invested

Capital invested by funds: $812M → $716M (-$95.6M)

Holders
73
Holders Change
+8
Holders Change %
+12.31%
% of All Funds
1.05%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
18
Increased
31
Reduced
16
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SFM
26
Sphera Funds Management
Israel
$2.55M +$1.53M +80,506 +107%
Goldman Sachs
27
Goldman Sachs
New York
$1.49M +$1.14M +59,862 +195%
CH
28
CVI Holdings
Delaware
$1.15M +$1.33M +70,000 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.14M +$136K +7,146 +12%
Jane Street
30
Jane Street
New York
$985K -$409K -21,518 -26%
N
31
Nuveen
North Carolina
$920K
Ensign Peak Advisors
32
Ensign Peak Advisors
Utah
$821K
VOYA Investment Management
33
VOYA Investment Management
Georgia
$742K -$78.4K -4,125 -8%
Bank of America
34
Bank of America
North Carolina
$692K +$377K +19,838 +89%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$664K -$136K -7,129 -15%
AA
36
ALPS Advisors
Colorado
$504K +$584K +30,702 New
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$503K +$71.6K +3,765 +14%
UBS Group
38
UBS Group
Switzerland
$456K -$357K -18,799 -40%
Swiss National Bank
39
Swiss National Bank
Switzerland
$445K -$26.6K -1,400 -5%
Deutsche Bank
40
Deutsche Bank
Germany
$441K -$38.8K -2,042 -7%
AllianceBernstein
41
AllianceBernstein
Tennessee
$425K +$86.7K +4,560 +21%
BOTOTLSJU
42
Board of Trustees of The Leland Stanford Junior University
California
$382K +$442K +23,273 New
Morgan Stanley
43
Morgan Stanley
New York
$380K -$288K -15,122 -40%
LCM
44
Landscape Capital Management
New Jersey
$357K +$71.4K +3,755 +21%
Verition Fund Management
45
Verition Fund Management
Connecticut
$354K +$409K +21,536 New
UOC
46
UBS O'Connor
Illinois
$328K +$380K +20,000 New
Barclays
47
Barclays
United Kingdom
$283K -$62.9K -3,306 -16%
Legal & General Group
48
Legal & General Group
United Kingdom
$269K +$33.6K +1,765 +12%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$229K -$21.8K -1,145 -8%
UBS AM
50
UBS AM
Illinois
$214K +$248K +13,034 New

CRGX Hedge Fund Activity: Q2 2024 in Review

73 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CARGO Therapeutics (CRGX) for Q2 2024, worth a combined $716M — down 12% from $812M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CRGX positions and 9 closed out — a net gain of 9 holders — while 31 added to existing stakes and 16 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $27.9M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $3.3M sold.

  • 73 institutional investors held CARGO Therapeutics (CRGX) as of Q2 2024, up from 65 in Q1 2024.
  • Funds reported $716M of CARGO Therapeutics stock for Q2 2024, down 12% quarter-over-quarter.
  • 18 funds opened new CARGO Therapeutics positions in Q2 2024 and 9 closed out, a net change of +9 holders.
  • The largest CARGO Therapeutics buyer in Q2 2024 was EcoR1 Capital, an estimated $27.9M added.
  • The largest CARGO Therapeutics seller in Q2 2024 was Paradigm Biocapital Advisors, an estimated $3.3M sold.

Based on aggregated 13F filings for Q2 2024.